Adlai Nortye Group Ltd. ANL
Adlai Nortye Group Ltd. (Nasdaq: ANL) is an oncology drug developer. Its lead program, AN4035, is in Phase 1 for CEACAM5-enriched, RAS-addicted solid tumors (colorectal, pancreatic, lung). Its next catalyst on record is AN4035: Report full Phase Ia data (H2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: AN4035 — Report full Phase Ia data (H2 2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Buparlisib (AN2025) | Recurrent/metastatic HNSCC after anti-PD-1/PD-L1 therapy | small molecule | Phase 3 |
| AN4035 (CEACAM5-targeting pan-RAS(ON) inhibitor ADC) | CEACAM5-enriched RAS-addicted solid tumors | antibody | Phase 1 |
| AN9025 (oral pan-RAS(ON) inhibitor) | RAS-driven cancers (not stated in supplied text) | small molecule | Phase 1 |
| AN8025 (multi-functional PD-1/L1 pathway fusion protein) | Solid tumors (not stated in supplied text) | protein/peptide | Phase 1 |
Recent results and decisions
- Aug 14, 2026positive Randomized Phase 2 ARTEMIS passed its futility analysis in March 2026; no efficacy data given.
The futility analysis of this Phase II study was successfully passed in March 2026, and the topline results are expected in the first half of 2027.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
- Erasca, Inc. ERAS
- Parabilis Medicines, Inc. PBLS
- Xencor Inc XNCR
- Schrodinger, Inc. SDGR
- Vir Biotechnology, Inc. VIR
- Zymeworks Inc. ZYME
- Janux Therapeutics, Inc. JANX
- Aktis Oncology, Inc. AKTS
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.